FINWIRES · TerminalLIVE
FINWIRES

BP Cheers 'Strong' First-quarter Earnings as Iran War Leads to 'Exceptional' Oil Trading

By

-- BP (BP.L) clocked upbeat results for the first quarter on Tuesday, thanks to "significantly" higher realized margins and an "exceptional" contribution from oil trading as the ongoing Iran war keeps prices elevated.

Profit attributable to shareholders for the three months ended March 31 surged year over year to $3.84 billion from $687 million. Adjusted for certain items, the underlying replacement cost profit reached $3.2 billion, up from $1.38 billion a year ago.

Total revenue and other income increased annually to $53.37 billion from $47.88 billion, with the oil and gas giant touting a sequential improvement in upstream plant reliability to 95.7% from 95.4% in the previous quarter. Reported upstream production remained broadly stable as higher production in the Gulf of America and strong performance in bpx Energy offset the impact of disruptions in the Middle East.

On the downstream side, BP's refining availability moved up to 96.3% in the first quarter of 2026 from 96% in the previous three months, exceeding the company's target of 96% availability.

"BP reported strong numbers this morning, with a 20% beat vs. market expectations at the net income level (7% ahead of RBCe)," RBC Capital Markets said. "Looking divisionally, the star of the show was the downstream, with BP reporting higher refining & trading numbers, well in excess of consensus and ~$200m ahead of our estimates for the quarter, supported by exceptional oil trading results."

Against this backdrop, the board declared a higher interim dividend per ordinary share of $0.0832, compared with $0.08 in the prior-year period, payable June 26 to shareholders on record May 15. BP anticipates raising its dividend annually by at least 4% per ordinary share.

Moving ahead, reported upstream production for the three months ending June 30 was guided lower on a quarterly basis owing to the ongoing conflict in the Middle East and seasonal maintenance, mainly in the Gulf of America. For full year 2026, reported upstream production is also expected to decline from the previous year.

The company's stock rose over 2% in early morning trade.

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS